{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:33:42Z","timestamp":1778283222896,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T00:00:00Z","timestamp":1355356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In this prospective study of patients with relapsed or relapsed and refractory multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>) treated with lenalidomide and dexamethasone, relationships between markers of endothelial stress and drug administration and incidence of venous thromboembolism (<jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>) were assessed. Of 33 enrolled patients, laboratory and treatment data were available for 32 patients. Of these, 23 received pulsed dexamethasone (40\u00a0mg\/day on days 1\u20134, 9\u201312 and 17\u201321 of each 28\u2010day cycle) and 9 received weekly dexamethasone (40\u00a0mg\/day on days 1, 8, 15 and 21 of each cycle). The overall incidence of <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content> was 9%. A decreasing trend in markers values was observed with intercellular adhesion molecule (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b705), fibrinogen (<jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0\u00b7008), plasminogen activator inhibitor\u20101 (<jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0\u00b7001), homocysteine (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7002) and P\u2013selectin (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00\u00b7001) during therapy. Compared with weekly dexamethasone, pulsed dexamethasone was associated with significantly greater variation in mean adjusted relative values of fibrinogen, P\u2010selectin and vascular endothelial growth factor (<jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0\u00b7001 for all comparisons), although there was no apparent association with <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content> incidence. Lenalidomide plus dexamethasone affects endothelial stress marker levels in patients with advanced <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>. The higher variation seen with pulsed dexamethasone suggests greater endothelial stress with this approach.<\/jats:p>","DOI":"10.1111\/bjh.12152","type":"journal-article","created":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T02:25:15Z","timestamp":1355451915000},"page":"351-358","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study"],"prefix":"10.1111","volume":"160","author":[{"given":"Rachel","family":"Rosovsky","sequence":"first","affiliation":[{"name":"Medical Oncology Massachusetts General Hospital Boston MA USA"},{"name":"Harvard Medical School Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangxin","family":"Hong","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Biostatistics and Computational Biology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Tocco","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Connell","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine","family":"Mitsiades","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Schlossman","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Lockridge","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Warren","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Bradwin","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Laboratory Medicine Children's Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Doyle","sequence":"additional","affiliation":[{"name":"Instrumentation Laboratory Lexington MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edie","family":"Weller","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana\u2013Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.21.2558-c"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.6.715"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800910791054239"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood.V112.11.1740.1740","article-title":"Effect of venous thrombotic events on overall survival in multiple myeloma: analysis of thrombotic events occurring in e4a03a randomized trial of lenalidomide plus high\u2010dose dexamethasone (rd) versus lenalidomide plus low\u2010dose dexamethasone (rd) in newly diagnosed multiple myeloma, a trial coordinated by the Eastern Cooperative Oncology Group (ECOG)","volume":"112","author":"Jacobus S.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6802"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.190"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348896"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood.V116.21.859.859","article-title":"Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low\u2010dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009\u201002","volume":"116","author":"Leleu X.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1270"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.017913"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2817"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0221"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015909"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.6004\/jnccn.2007.0015","article-title":"The emerging role of novel therapies for the treatment of relapsed myeloma","volume":"5","author":"Richardson P.G.","year":"2007","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2679"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613051"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.052"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00393.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07013.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.11.017"},{"key":"e_1_2_7_26_1","first-page":"513s","article-title":"Pomalidomide (POM) with or without low\u2010dose dexamethasone (LoDEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and\/or bortezomib (BORT)","volume":"30","author":"Vij R","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12152","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T20:43:47Z","timestamp":1698698627000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,13]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/bjh.12152"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12152","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,13]]},"assertion":[{"value":"2012-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-12-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}